Education
About Us
Working with TipRanks
Follow Us
Kaleido Biosciences (KLDO)
:KLDO
KLDO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.04
Previous CloseN/A
Volume300.00
Average Volume (3M)374.00
Market Cap
$43.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-397.99
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,622,560
10 Day Avg. Volume374
30 Day Avg. Volume374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
KLDO FAQ
What was Kaleido Biosciences’s price range in the past 12 months?
Kaleido Biosciences lowest stock price was $0.01 and its highest was $0.04 in the past 12 months.
What is Kaleido Biosciences’s market cap?
Kaleido Biosciences’s market cap is $43.00.
When is Kaleido Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kaleido Biosciences’s earnings last quarter?
Currently, no data Available
Is Kaleido Biosciences overvalued?
According to Wall Street analysts Kaleido Biosciences’s price is currently Overvalued.
Does Kaleido Biosciences pay dividends?
Kaleido Biosciences does not currently pay dividends.
What is Kaleido Biosciences’s EPS estimate?
Kaleido Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaleido Biosciences have?
Kaleido Biosciences has 42,622,560 shares outstanding.
What happened to Kaleido Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kaleido Biosciences?
Currently, no hedge funds are holding shares in KLDO
Company Description
Kaleido Biosciences
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Technical Analysis
Biodexa Pharmaceuticals
―
TNF Pharmaceuticals
―
Soligenix
―
Salarius Pharmaceuticals
―
Oragenics
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---